Febuxostat for hyperuricemia: Experience with patients on chronic hemodialysis treatment

摘要

Febuxostat a non-purine xanthine oxidase inhibitor, which recently received marketing approval, has used as an option for the treatment of hyperuricemia because it undergoes hepatic metabolism and may require less dose adjustment in association with renal function 1. However, information regarding the therapeutic benefit of such an agent among chronic kidney disease (CKD) patients is limited. We would like to present our experience with five cases of chronic hemodialysis (HD) patients whose hyperuricemia was successfully treated by oral febuxostat with no apparent adverse events. All patients were male with an average age of 66.6 ± 18.5 years.